Introduced in House Passed House Introduced in Senate Passed Senate To President Became Law
02/13/2020          

Transparency in Prescription Drug Advertising Act

Date Version PDF TXT
01/01/2111 Open
02/13/2020 Introduced in House Open

            
        

Picture Name From Date Type
Sharice Davids D-KS 02/13/2020 Sponsor
Elissa Slotkin D-MI 02/13/2020 Cosponsor
Ed Perlmutter D-CO 05/01/2020 Cosponsor
Abby Finkenauer D-IA 02/13/2020 Cosponsor
Date Branch Action
02/13/2020 President Referred to the House Committee on Energy and Commerce.Action By: House of Representatives
02/13/2020 President Introduced in HouseAction By: House of Representatives
Summary
There is one summary for H.R.5894. View summaries Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.
Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.
Congress - Bill Number Major Title
Branch Vote Date Yes No Not Voting
Wiki







Bill TEXT Points.
This Bill has been listed with the following Subjects from Texts:
Commerce
Finkenauer) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo direct the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs

Congress


Drugs
Pricing transparency in drug advertising(a)In generalNot later than one year after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with the Commissioner of Food and Drugs and the Administrator of the Centers for Medicare & Medicaid Services, shall issue department-wide guidance requiring the list prices of drugs to be included, as appropriate, in all advertising of drugs, including by means of television, newspapers, the internet, or other media

Energy
Finkenauer) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo direct the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs


End Bill TEXT Points.
Date Bill Major Title
Committee Name
Subject Type